Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?

Thank you to Madrigal for your support of this Medication Review Video Module.In this Medication Review Video Module, Whitney Steinmetz, NP, provides an in-depth discussion on the clinical profile of Retam (Resd) for Metabolic-Associated Steatohepatitis (MASH) with moderate to advanced F2 or F3 fibrosis. While Retam is not currently FDA-approved for patients with cirrhosis, ongoing trials are evaluating its potential in this population.As a partial agonist of the thyroid hormone receptor beta, Retam targets hepatic metabolism, reducing intrahepatic triglycerides and improving liver health without significantly affecting thyroid hormone receptor alpha—which mediates effects on the heart and bones. The 52-week study demonstrated its effectiveness in resolving steatohepatitis and improving fibrosis without worsening inflammation.Available in 60 mg, 80 mg, and 100 mg tablets, dosage is weight-based, with 80 mg recommended for patients under 100 kg and 100 mg for those over 100 kg. Due to its metabolism via CYP2C8, Retam should not be used with strong inhibitors like gemfibrozil, and statin doses may require adjustment.Common side effects include nausea and diarrhea, which typically resolve over time. Mild serum aminotransferase elevations may occur early in treatment but often decrease within 3-6 months, correlating with reductions in hepatic fat and steatohepatitis.For more expert insights on MASH management, visit the GHAPP website or the GHAPP ACE app.